Innate Pharma SA
IPHA
Company Profile
Business description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Contact
117, Avenue de Luminy
Marseille13009
FRAT: +33 430303030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
179
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,471.50 | 18.80 | 0.22% |
| CAC 40 | 7,282.69 | 10.37 | 0.14% |
| DAX 40 | 19,848.77 | 35.98 | -0.18% |
| Dow JONES (US) | 43,297.03 | 390.08 | 0.91% |
| FTSE 100 | 8,136.99 | 34.27 | 0.42% |
| HKSE | 20,098.29 | 215.16 | 1.08% |
| NASDAQ | 20,031.13 | 266.24 | 1.35% |
| Nikkei 225 | 39,568.06 | 437.63 | 1.12% |
| NZX 50 Index | 13,074.74 | 86.71 | 0.67% |
| S&P 500 | 6,040.04 | 65.97 | 1.10% |
| S&P/ASX 200 | 8,220.90 | 19.30 | 0.24% |
| SSE Composite Index | 3,393.53 | 42.27 | 1.26% |